Phase I–II constant infusion of adriamycin (doxorubicin) by ambulatory pump delivery system in heavily pretreated (including adriamycin) breast cancer patients-Reference-Cited by-同舟云学术

Phase I–II constant infusion of adriamycin (doxorubicin) by ambulatory pump delivery system in heavily pretreated (including adriamycin) breast cancer patients

Published:1990 Issue:3 Volume:1 Page:189-193
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Jasmin C.,Gil-Delgado M.A.,Marino J.P.,Ecstein E.,Descorps-Declere A.,Misset J.L.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/1/3/189/6672320/1-3-189.pdf

Reference23 articles.

1. Risk factors for doxorobicin induced congestive heart failure;Von Hoff;Ann Intern Med,1979

2. Adriamycin cardiomyopathy. Risk factors;Minow;Cancer,1977

3. A clinicopathologic analysis of adriamycin cardiotoxicity;Lefrak;Cancer,1973

4. Adriamycin (NSC 123-127) cardiomyopathy - an overview with determination of risk factors;Minow;Cancer chemotherapy Rep,1975

5. Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system;Lokich;J of Clin Oncol,1983

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of bolus administration and short-term infusion versus long-term infusion of doxorubicin in terms of cardiotoxicity and efficacy;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-12-14

2. SQ3370, the first clinical click chemistry-activated cancer therapeutic, shows safety in humans and translatability across species;2023-03-29

3. Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin;Cancer Treatment Communications;2015

4. p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance;BMC Cancer;2010-07-22

5. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer;Seminars in Oncology;2004-12